Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genentech And Array Join ChK-1 Programs
by Lisa M. Jarvis
August 15, 2011
| A version of this story appeared in
Volume 89, Issue 33
Genentech will pay Array BioPharma $28 million as part of a deal to jointly develop the companies’ small-molecule inhibitors of Checkpoint kinase 1 (ChK-1), a protein implicated in cancer cell survival. Included in the pact are Genentech’s GDC-0425, in Phase I studies, and Array’s ARRY-575, which has yet to be tested in humans. Array could gain up to $685 million in milestone payments along with royalties on any drug that is commercialized under the pact from either firm. ChK-1 helps a tumor cell to repair damaged DNA after exposure to chemotherapy; if the protein is blocked, chemotherapy should kill cancer cells more effectively.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter